The difference between trifluridine, tipiracil (Lancever) and bevacizumab

Trifluridine and bevacizumab are two different drugs used to treat different types of diseases, with differences in their mechanisms of action. However, according to the approval of the U.S. Food and Drug Administration (FDA), trifluridine tipiracil can be used in combination with bevacizumab to treat colorectal cancer in people who have been treated with other chemotherapy drugs or who are unable to receive these chemotherapy drugs.

Trifluridine tipiracil (Lonsurf): is a chemotherapy drug mainly used to treat colorectal cancer, gastric cancer and other digestive system malignant tumors. It belongs to the fluorouracil class of drugs, which inhibits the synthesis of deoxyuridylic acid and interferes with DNA replication, thereby quickly inhibiting cancer cells. In addition, tipiracil enhances the effect of fluorouracil and further reduces the proliferation of cancer cells by inhibiting thymidine kinase. Trifluridine and tipiracil are often combined with other anticancer drugs to increase the effectiveness of treatment.

Bevacizumab is a targeted therapy drug, also known as an anti-angiogenic drug (VEGF antibody). VEGF, short for vascular endothelial growth factor, plays an important role in tumor growth and spread by promoting blood vessel formation to provide nutrients to cancer cells. Bevacizumab inhibits tumor growth by binding to and neutralizing VEGF, blocking the formation of new blood vessels, and cutting off the nutrient supply to tumors. Bevacizumab is commonly used in the treatment of a variety of solid tumors, including non-small cell lung cancer, colorectal cancer, renal cancer, etc., especially those with rich blood vessels.

In summary, trifluridine and tipiracil are mainly used as chemotherapy drugs to treat cancer by directly inhibiting the proliferation of cancer cells, while bevacizumab indirectly inhibits tumor growth through an anti-angiogenic mechanism. There are significant differences in the mechanism of action and indications between the two, and they cannot replace each other. In clinical practice, doctors will choose appropriate treatment options based on the patient's condition and tumor characteristics.